Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

University of Calgary

$140,000.00

Developing novel chimeric antigen receptor double-negative T-cell therapy for acute myeloid leukemia

EF 2025-26

Résumé
Adoptive cellular therapy (ACT) is a treatment method that involves infusing human immune cells into patients to fight diseases like cancer. One form of ACT uses genetically engineered (GE)-T cells, a major type of white blood cell, to kill cancer cells based on a selected molecule found on the cancer cell surface. While successful with certain blood cancers, its application to acute myeloid leukemia (AML), the most common form of adult acute leukemia, has been challenging due to the inability to find safe and effective target molecules on all AML cells. AML cells are very similar to normal stem cells, essential cells that develop into all types of blood cells, and have different characteristics between patients or within the same patient. This project focuses on a rare subtype of T cells called double-negative T cells (DNTs), which can kill AML while sparing healthy cells without any modifications. However, some AML cells cannot be killed by DNTs. The objective is to develop GE-DNTs to better target AML cells and understand their anti-cancer mechanisms. I hypothesize that GE-DNTs will 1) have increased AML-targeting abilities while 2) aiding nearby T cells to further kill AML. Recently, we identified a new molecule found on AML, but not normal stem cells called VSTM1. First, GE-DNTs will be manufactured to target VSTM1. Next, the efficacy and safety of the GE-DNTs will be compared to two other groups: unmodified DNTs and GE-T cells. Each treatment group will be mixed with AML patient samples or injected into mice with AML patient samples. The level of AML cell death and mouse health will be assessed between groups. Also, we will conduct genetic analyses on samples recovered from the mice, containing GE-DNTs and patient samples. Since patient samples have AML cells and some normal T cells, we can infer and validate how GE-DNTs interact with a patients' T cells to further kill AML. Overall, this project aims to develop a safe and effective GE-DNT therapy for AML.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
536718
Name
Tin Enoch
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Developing novel chimeric antigen receptor double-negative T-cell therapy for acute myeloid leukemia
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Acute Myeloid Leukemia; Adoptive Cellular Therapy; Cancer Immunotherapy; Chimeric Antigen Receptor-T Cell Therapy; Double-Negative T Cells; Single-Cell Rna Sequencing; Xenograft Mouse Models
Abstract
Adoptive cellular therapy (ACT) is a treatment method that involves infusing human immune cells into patients to fight diseases like cancer. One form of ACT uses genetically engineered (GE)-T cells, a major type of white blood cell, to kill cancer cells based on a selected molecule found on the cancer cell surface. While successful with certain blood cancers, its application to acute myeloid leukemia (AML), the most common form of adult acute leukemia, has been challenging due to the inability to find safe and effective target molecules on all AML cells. AML cells are very similar to normal stem cells, essential cells that develop into all types of blood cells, and have different characteristics between patients or within the same patient. This project focuses on a rare subtype of T cells called double-negative T cells (DNTs), which can kill AML while sparing healthy cells without any modifications. However, some AML cells cannot be killed by DNTs. The objective is to develop GE-DNTs to better target AML cells and understand their anti-cancer mechanisms. I hypothesize that GE-DNTs will 1) have increased AML-targeting abilities while 2) aiding nearby T cells to further kill AML. Recently, we identified a new molecule found on AML, but not normal stem cells called VSTM1. First, GE-DNTs will be manufactured to target VSTM1. Next, the efficacy and safety of the GE-DNTs will be compared to two other groups: unmodified DNTs and GE-T cells. Each treatment group will be mixed with AML patient samples or injected into mice with AML patient samples. The level of AML cell death and mouse health will be assessed between groups. Also, we will conduct genetic analyses on samples recovered from the mice, containing GE-DNTs and patient samples. Since patient samples have AML cells and some normal T cells, we can infer and validate how GE-DNTs interact with a patients' T cells to further kill AML. Overall, this project aims to develop a safe and effective GE-DNT therapy for AML.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tin, Enoch
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~